SecBot SecBot

SPRO drug pipeline

Spero Therapeutics, Inc. · 2 rated drugs
$0.9460
−5.4% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±8.3%
1-day, median of 3 events
IV rank
No data
No current options data
Rated drugs
2
2 mixed
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 2-ready (Phase 1 completed in healthy volunteers and Sjögren's disease)
Time to market5+ years (Phase 2 starting Q2 2027; IgG4-RD is an orphan indication but still requires Phase 2 and Phase 3)

SP001 IBI355 Updated Jul 14

What to watch

SP001 is a new pipeline asset for Spero, announced alongside a $105M non-dilutive royalty financing from Utebzi sales. Watch for the Phase 2 initiation in IgG4-RD (Q2 2027) as the next catalyst. The stock may re-rate on execution towards Phase 2 start, but the $1.1B milestone burden relative to Spero's ~$126M market cap is a significant overhang. Monitor Innovent's Phase 2 SjD data in China (early 2027) as a read-through for the mechanism.

Bull case
  • SP001 is a third-generation Fc-silent anti-CD40L antibody, a clinically validated mechanism with built-in safety improvements over first-gen drugs that caused thrombotic side effects. Phase 1 data in healthy volunteers and Sjögren's patients have been presented at EULAR 2026, de-risking the asset.
  • Spero simultaneously raised $105M via non-dilutive Healthcare Royalty financing backed by recently approved Utebzi (tebipenem) royalties, providing cash to fund SP001 development without immediate shareholder dilution.
  • IgG4-related disease is a rare autoimmune indication with high unmet need, a successful development path could command orphan-drug pricing and a focused commercial strategy.
Bear case
  • SP001 is still preclinical for IgG4-RD, the lead Spero indication. Only Phase 1 healthy-volunteer and Sjögren's data exist, efficacy in IgG4-RD is unproven. Phase 2 may fail or be delayed.
  • The deal carries up to ~$1.1B in milestone obligations to Innovent, a massive liability relative to Spero's ~$126M market cap. Even modest success triggers payments that could strain the balance sheet.
  • Competition is mounting: inebilizumab (anti-CD19) recently showed an 87% reduction in IgG4-RD flares in Phase 3, and other anti-CD40L antibodies (dapirolizumab, amlitelimab) are in development for overlapping indications.
◆ mixed
Impact
PhaseApproved
Time to marketAlready approved (FDA approval June 17, 2026). GSK is now commercializing the drug.

tebipenem HBr tebipenem pivoxil hydrobromide Updated Jun 30

What to watch

The approval binary has passed; the stock now trades on Utebzi commercial uptake (milestones/royalties from GSK) rather than catalyst-driven moves. Watch for GSK's commercial launch updates and any milestone-triggering events. The rest of Spero's pipeline is weak (SPR720 Phase 2a failed, SPR206 halted), making this a pure-play royalty/milestone story off a single approved drug.

Bull case
  • Utebzi is the first and only oral carbapenem approved in the US, a clear first-mover advantage for treating complicated UTIs without hospitalization, addressing a significant unmet need (3M+ cases/year).
  • The Phase 3 PIVOT-PO trial was stopped early for efficacy, demonstrating non-inferiority to IV imipenem-cilastatin, a strong data package supporting adoption.
  • GSK is a top-tier commercial partner with deep anti-infective experience; Spero is eligible for up to $525M in milestones plus tiered royalties (low-single to low-double digit) with no commercial risk.
Bear case
  • The approval binary has passed, stock saw a ~245% surge on the Phase 3 readout and only ~16% on approval, suggesting much of the upside is already priced in.
  • Spero's pipeline beyond Utebzi is weak: SPR720 Phase 2a missed its primary endpoint for NTM pulmonary disease, and SPR206 was halted in March 2025, making the company a single-asset story with no near-term binary catalysts.
  • Analyst consensus skews bearish: 0 buy ratings, 3 holds, 1 sell, and 2 strong sells per latest data, reflecting skepticism about valuation.

Past FDA events & how the stock moved

3 events
DateDrugEvent1 day5 days
Jun 18, 2026tebipenem HBrPDUFA decision+4.7%+7.1%
Jun 17, 2026tebipenem HBrApproval−17.7%−27.1%
Dec 1, 2025tebipenem HBrNDA filed−8.3%−3.8%